Bio-Rad Laboratories (BIO) EBITDA (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of EBITDA data on file, last reported at $34.1 million in Q1 2026.

• EBITDA for Q1 2026 came in at $34.1 million, up 43.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $57.6 million (down 76.77% YoY), and the FY2025 annual result was $47.2 million, down 82.45% from the prior year.
• EBITDA grew to $34.1 million in Q1 2026 per BIO's latest filing, from -$118.9 million in the prior quarter.
• Over five years, EBITDA peaked at $146.4 million in Q1 2022 and troughed at -$118.9 million in Q4 2025.
• A 5-year average of $68.9 million and a median of $77.1 million in 2025 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2025: EBITDA soared 45.16% in 2022, then tumbled 303.95% in 2025.
• A 5-year view of EBITDA shows it stood at $118.7 million in 2022, then decreased by 19.66% to $95.3 million in 2023, then tumbled by 38.84% to $58.3 million in 2024, then plunged by 303.95% to -$118.9 million in 2025, then jumped by 128.68% to $34.1 million in 2026.
• Business Quant data shows BIO's EBITDA at $34.1 million in Q1 2026, -$118.9 million in Q4 2025, and $65.3 million in Q3 2025.